Antares Vision Srl partners with Xyntek, Inc. for US market
Even though serialization and track-and-trace rules did not make the final cut of the FDA Safety and Innovation Act signed into law in July, a growing number of pharma manufacturers and contract packagers are installing necessary hardware and software now. Part of the rationale is the upcoming e-pedigree rules scheduled to go into force in California in 2015 (these would have been superseded had federal legislation passed); and another factor is the growing number of countries outside the US that have implementation deadlines in place.
The latest set of players to enter the arena are Xyntek, Inc., a Yardley, PA, systems integrator with experience in packaging, quality management and regulatory support, which is partnering with Anatares Srl (Brescia, Italy), a machine-vision company serving the life sciences markets in Europe, South America and Asia. Antares claims to have more than 250 packaging lines using its machine vision and serialization technology. It also has a year-old partnership with Cognex, Inc. (Natick, MA), an industry leader in machine vision systems.
Serialization is a necessary first step to industry-wide track-and-trace systems, but by no means the sufficient step. Standardization among industry trading partners, and the willingness (or regulatory requirement) to share pedigree information are still to be worked out.
Machine Health in Pharmaceutical Production
December 2nd 2024Predictive maintenance in pharmaceutical production can help reduce downtime and increase efficiency. Grundfos Machine Health (GMH) uses artificial intelligence (AI)-driven wireless sensors to monitor motor health in real-time, identifying potential issues. This approach not only reduces maintenance costs but also ensures compliance with industry standards.
Newron, Myung In Pharm Form Partnership Centered Around Treating Schizophrenia in South Korea
January 14th 2025The license agreement will feature an upcoming Phase III trial and—depending on results—the development, manufacturing, and commercialization of evenamide as a potential treatment option.